HMPL-760をR-GemOxと併用した場合と、プラセボをR-GemOxと併用した場合を比較する、再発・難治性DLBCL患者を対象とした第III相試験
HMPL-760とR-GemOxの併用療法と、プラセボとR-GemOxの併用療法を比較する、再発・難治性びまん性大細胞型B細胞性リンパ腫(DLBCL)患者を対象とした第III相ランダム化二重盲検陽性対照試験:有効性、安全性、薬物動態の評価
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
調査の概要
詳細な説明
The study phases include screening period, treatment period, safety observation period, PFS follow-up period, and OS follow-up period.
The target population of this study includes patients with DLBCL who are relapsed or refractory.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Dongmei Chen, CPL
- 電話番号:86-21-20671794
- メール:dongmeic@hutch-med.com
研究場所
-
-
-
Baoding、中国
- 募集
- Baoding NO.1 Central Hospital
-
コンタクト:
- Haiying Yao
- 電話番号:18617789030
- メール:haiyingyaobd@163.com
-
主任研究者:
- Haiying Yao
-
Beijing、中国
- 募集
- Beijing GoBroad Hospital
-
主任研究者:
- Kai Hu
-
コンタクト:
- Kai Hu
- 電話番号:15010390336
- メール:HK13610956245@163.com
-
Beijing、中国
- 募集
- BEIJING TONGREN HOSPITAL, Capital Medical University
-
主任研究者:
- Liang Wang
-
コンタクト:
- Liang Wang
- 電話番号:15001108693
- メール:wangliangtrhos@126.com
-
Bengbu、中国
- 募集
- The First Affiliated Hospital of Bengbu Medical College
-
コンタクト:
- Yanli Yang
- 電話番号:13855249678
- メール:Yangyanli0702@126.com
-
主任研究者:
- Yanli Yang
-
Changchun、中国
- 募集
- The First Hospital of Jilin University
-
主任研究者:
- Ou Bai
-
コンタクト:
- Ou Bai
- 電話番号:13039046656
- メール:lbl2054@163.com
-
Changsha、中国
- 募集
- Hunan Cancer Hospital
-
主任研究者:
- Hui Zhou
-
コンタクト:
- Hui Zhou
- 電話番号:13975879796
- メール:zhouhui9403@126.com
-
Changsha、中国
- 募集
- The Second Xiangya Hospital of Central South University
-
主任研究者:
- Hongling Peng
-
コンタクト:
- Hongling Peng
- 電話番号:18900766137
- メール:Penghongling@aliyun.com
-
Changsha、中国
- 募集
- People's Hospital of Hunan Province
-
コンタクト:
- Can Liu
- 電話番号:137 8728 5260
- メール:617170469@qq.com
-
主任研究者:
- Can Liu
-
Chengdu、中国
- 募集
- West China Hospital of Sichuan University
-
主任研究者:
- Liqun Zou
-
コンタクト:
- Liqun Zou
- 電話番号:18980601027
- メール:Clinical_Zou@163.com
-
Chengdu、中国
- 募集
- Sichuan Provincial People's Hospital
-
コンタクト:
- Xiaobing Huang
- 電話番号:18981838236
- メール:hxb_trial@163.com
-
主任研究者:
- Xiaobing Huang
-
Chongqing、中国
- 募集
- The First Affiliated Hospital of Chongqing Medical University
-
主任研究者:
- Xin Wang
-
コンタクト:
- Xin Wang
- メール:925170788@qq.com
-
Chongqing、中国
- 募集
- Chongqing University Cancer Hospital
-
主任研究者:
- Yao Liu
-
コンタクト:
- Yao Liu
- メール:liuyao101709@163.com
-
Fujian、中国
- 募集
- Quanzhou First Hospital.Fujian
-
コンタクト:
- Xiongpeng Zhu
- 電話番号:13805998581
- メール:xiongpengzhu@163.com
-
主任研究者:
- Xiongpeng Zhu
-
Fuzhou、中国
- 募集
- Fujian Medical University Union Hospital
-
主任研究者:
- Jianzhen Shen
-
コンタクト:
- Jianzhen Shen
- 電話番号:138 0955 2722
- メール:doctorsjz@163.com
-
Guangzhou、中国
- 募集
- Sun Yat-sen University Cancer Center
-
主任研究者:
- Zhiming Li
-
コンタクト:
- Zhiming Li
- 電話番号:13719189172
- メール:lzmsysu@163.com
-
Guangzhou、中国
- 募集
- Guangdong Provincial People's Hospital
-
コンタクト:
- Xiaojuan Wei
- 電話番号:86 13560097145
- メール:jxw919@hotmail.com
-
主任研究者:
- Xiaojuan Wei
-
Guangzhou、中国
- 募集
- ZhuJiang Hospital of Southern Medical University(The Second Clinical Medical College)
-
主任研究者:
- Yuhua Li
-
コンタクト:
- Yuhua Li
- 電話番号:13533706656
- メール:liyuhua2011gz@163.com
-
Guiyang、中国
- 募集
- The Affiliated Hospital of Guizhou Medical University
-
主任研究者:
- Yan Zhang
-
コンタクト:
- Yan Zhang
- 電話番号:86 18984155172
- メール:Zhangyan20010802@sina.com
-
Hangzhou、中国
- 募集
- Zhejiang Cancer Hospital
-
主任研究者:
- Haiyan Yang
-
コンタクト:
- Haiyan Yang
- メール:2054451461@qq.com
-
Hangzhou、中国
- 募集
- The First Affiliated Hospital, Zhejiang University
-
主任研究者:
- Zhen Cai
-
コンタクト:
- Zhen Cai
- 電話番号:13857190311
- メール:czclinicaltrial@163.com
-
Harbin、中国
- 募集
- Harbin Medical University Cancer Hospital
-
コンタクト:
- Qingyuan Zhang
- 電話番号:13313612989
- メール:sy86298276@163.com
-
主任研究者:
- Qingyuan Zhang
-
Hefei、中国
- 募集
- The Second Affiliated Hospital of Anhui Medical University
-
コンタクト:
- Zhimin Zhai
- 電話番号:13855147434
- メール:zzzm889@163.com
-
主任研究者:
- Zhimin Zhai
-
Jinan、中国
- 募集
- Qilu Hospital of Shandong University
-
コンタクト:
- Shuqian Xu
- 電話番号:18560087013
- メール:yoyoshuqian@126.com
-
主任研究者:
- Shuqian Xu
-
Jinan、中国
- 募集
- Shandong Cancer Hospital & Institute
-
主任研究者:
- Zengjun Li
-
コンタクト:
- Zengjun Li
- 電話番号:15735178591
- メール:zengjunli@163.com
-
Kunming、中国
- まだ募集していません
- The First Affiliated Hospital of Kunming Medical University
-
コンタクト:
- Mingxia Shi
- 電話番号:86 138 8806 0581
- メール:shmxia2002@sina.com
-
主任研究者:
- Mingxia Shi
-
Nanchang、中国
- 募集
- Jiangxi Cancer Hospital
-
主任研究者:
- Yan Huang
-
コンタクト:
- Yan Huang
- メール:29265061@qq.com
-
Nanjing、中国
- 募集
- Jiangsu Cancer Hospital
-
主任研究者:
- Yan Zhang
-
コンタクト:
- Yan Zhang
- 電話番号:13914712395
- メール:zhangyan1106@njmu.edu.cn
-
Nanjing、中国
- 募集
- Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
-
コンタクト:
- Jingyan Xu
- 電話番号:86 13951969610
- メール:xjy1967@sina.com
-
主任研究者:
- Jingyan Xu
-
Nanning、中国
- 募集
- The First Affiliated Hospital of Guangxi Medical University
-
主任研究者:
- Zhigang Peng
-
コンタクト:
- Zhigang Peng
- メール:2557382235@qq.com
-
Qingdao、中国
- 募集
- The Affiliated Hospital of Qingdao University
-
コンタクト:
- Xia Zhao
- 電話番号:18661803088
- メール:Zhaoxia@qdu.edu.cn
-
主任研究者:
- Xia Zhao
-
Shanghai、中国
- 募集
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine
-
主任研究者:
- Weili Zhao
-
コンタクト:
- Weili Zhao
- 電話番号:86 13512112076
- メール:zwl_trial@163.com
-
Shanghai、中国
- 募集
- Tongji Hospital of Tongji University
-
コンタクト:
- Ping Li
- 電話番号:13564181131
- メール:lilyforever76@126.com
-
主任研究者:
- Ping Li
-
Shanghai、中国
- まだ募集していません
- Tong Ren Hospital Shanghai Jiao Tong University School Of Medicine
-
主任研究者:
- Ligen Liu
-
コンタクト:
- Ligen Liu
- 電話番号:86 18017337037
- メール:llg3532@shtrhospital.com
-
Shenyang、中国
- 募集
- Shengjing Hospital of China Medical University
-
主任研究者:
- Wei Yang
-
コンタクト:
- Wei Yang
- 電話番号:18940251012
- メール:sjyangw@163.com
-
Shenzhen、中国
- 募集
- Shenzhen people's hospital
-
主任研究者:
- Jihao Zhou
-
コンタクト:
- Jihao Zhou
- 電話番号:86 18718678693
- メール:zhoujihao@aliyun.com
-
Taiyuan、中国
- 募集
- Shanxi Provincial Cancer Hospital
-
主任研究者:
- Liping Su
-
コンタクト:
- Liping Su
- 電話番号:13835158122
- メール:slpsy2022@163.com
-
Tangshan、中国
- 募集
- North China University of Science and Technology Affiliated Hospital
-
コンタクト:
- Zhenyu Yan
- 電話番号:15931508262
- メール:hbyzy2011@163.com
-
主任研究者:
- Zhenyu Yan
-
Tianjin、中国
- 募集
- Tianjin Medical University Cancer Institute & Hospital
-
主任研究者:
- Zhengzi Qian
-
コンタクト:
- Zhengzi Qian
- 電話番号:13702031222
- メール:qzz@163.com
-
Tianjin、中国
- 募集
- Tianjin People's Hospital
-
コンタクト:
- Xingli Zhao
- 電話番号:13752255454
- メール:insectzhao@163.com
-
主任研究者:
- Xingli Zhao
-
Tianjin、中国
- 募集
- Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
主任研究者:
- Dehui Zou
-
コンタクト:
- Dehui Zou
- 電話番号:13602100955
- メール:zoudehui@ihcams.ac.cn
-
Wenzhou、中国
- 募集
- The First Affiliated Hospital of WMU
-
コンタクト:
- Songfu Jiang
- 電話番号:86 15305770033
- メール:jiangsongfu@189.cn
-
主任研究者:
- Songfu Jiang
-
Wuhan、中国
- 募集
- Hubei Cancer Hospital
-
主任研究者:
- Huijing Wu
-
コンタクト:
- Huijing Wu
- メール:3269614878@qq.com
-
Wuhan、中国
- 募集
- Wuhan Union Hospital of China
-
主任研究者:
- Liling Zhang
-
コンタクト:
- Liling Zhang
- 電話番号:15871725926
- メール:lily1228@sina.com
-
Xi'an、中国
- 募集
- The First Affiliated Hospital of Xi'an Jiaotong University
-
主任研究者:
- Pengcheng He
-
コンタクト:
- Pengcheng He
- 電話番号:18991232609
- メール:hepc_gcp@163.com
-
Xi'an、中国
- 募集
- The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hosiptal)
-
主任研究者:
- Jie Liu
-
コンタクト:
- Jie Liu
- 電話番号:86 18092662371
- メール:lieujie@163.com
-
Xiamen、中国
- まだ募集していません
- The First Affiliated Hospital of Xiamen University
-
主任研究者:
- Bing Xu
-
コンタクト:
- Bing Xu
- 電話番号:86 18750918842
- メール:xubingzhangjian@126.com
-
Xuzhou、中国
- 募集
- The Affiliated Hospital of Xuzhou Medical University
-
コンタクト:
- Wei Sang
- 電話番号:86 13645207648
- メール:13645207648@126.com
-
主任研究者:
- Wei Sang
-
Zhengzhou、中国
- 募集
- Henan Cancer Hospital
-
主任研究者:
- Keshu Zhou
-
コンタクト:
- Keshu Zhou
- 電話番号:13674902391
- メール:dr_zkshu23810@163.com
-
Zhengzhou、中国
- 募集
- The First Affiliated Hospital of Zhengzhou University
-
コンタクト:
- Xudong Zhang
- 電話番号:13633825183
- メール:feverxxd@126.com
-
主任研究者:
- Xudong Zhang
-
Ürümqi、中国
- 募集
- People's Hospital of Xinjiang Uygur Autonomous Region
-
主任研究者:
- Yan Li
-
コンタクト:
- Yan Li
- 電話番号:86 13639935315
- メール:liyan232917@139.com
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- 募集
- Fudan University Shanghai Cancer Center
-
コンタクト:
- Fangfang Lv
- 電話番号:18017312613
- メール:Lvff80@163.com
-
主任研究者:
- Fangfang Lv
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Sign the ICF and be able to follow the requirements of study protocol;
- Age ≥18 years;
- ECOG performance status score between 0 and 2;
- Histopathologically confirmed diagnosis of DLBCL;
- The investigator judges that the patient's current condition requires further treatment;
- Patients should have at least one bi-dimensionally measurable lesion;
- Expected survival is more than 12 weeks;
Exclusion Criteria:
- Patients with known primary or secondary central nervous system lymphoma (CNSL) or the presence of clinical symptoms suggestive of CNSL;
- Women who are pregnant (positive pregnancy test during the screening period) or breastfeeding;
- Organ insufficiency;
- Currently known history of liver disease, including cirrhosis, alcoholic liver, known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV);
- History of significant organ bleeding, including gastrointestinal bleeding, hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of study drug;
- Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia; or the patient is receiving vitamin K antagonist (warfarin);
- The toxic reactions of previous anti-tumor therapy have not recovered to the level of ≤ grade 1 (except for alopecia and decreased appetite and other conditions that have been clearly required in the inclusion and exclusion criteria);
- Clinically significant active infection;
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:The experimental group
Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
Patients will receive HMPL-760 once daily (QD) orally. R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
他の名前:
|
|
プラセボコンパレーター:The control group
Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group. |
R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle.
他の名前:
Patients will receive HMPL-760 placebo once daily (QD) orally. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS)
時間枠:Up to approximately two years
|
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first. |
Up to approximately two years
|
|
End of treatment (EOT)
時間枠:Up to approximately two years
|
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy). |
Up to approximately two years
|
|
Systemic antitumor therapy
時間枠:Up to approximately two years
|
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy). |
Up to approximately two years
|
|
Overall survival (OS)
時間枠:Up to approximately two years
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately two years
|
|
systematic anti-tumor therapy
時間枠:Up to approximately two years
|
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
|
Premature withdrawal from study treatment
時間枠:Up to approximately two years
|
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy). |
Up to approximately two years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Independent review committee (IRC)-assessed PFS
時間枠:Up to approximately two years
|
Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). |
Up to approximately two years
|
|
IRC- and investigator-assessed objective response rate (ORR)
時間枠:Up to approximately two years
|
Objective Response Rate (ORR) is defined as the ratio of patients who reached complete response (CR) or partial response (PR) |
Up to approximately two years
|
|
IRC- and investigator-assessed complete response rate (CRR)
時間枠:Up to approximately two years
|
Complete response (CR) rate is defined as the ratio of patients with who reached complete response (CR) |
Up to approximately two years
|
|
IRC- and investigator-assessed duration of response (DoR)
時間枠:Up to approximately two years
|
For patients who reached complete response (CR) or partial response (PR), Duration of Response (DoR) is defined as the time from the first CR or PR until disease progression or death due to any cause, whichever occurs first |
Up to approximately two years
|
|
IRC- and investigator-assessed clinical benefit rate (CBR)
時間枠:Up to approximately two years
|
Defined as the ratio of patients with complete response (CR), partial response (PR), or stable disease (SD) |
Up to approximately two years
|
|
IRC- and investigator-assessed time to response (TTR)
時間枠:Up to approximately two years
|
Time To Response (TTR) is defined as the time from the start of treatment to the first objective response rate (ORR) |
Up to approximately two years
|
|
Safety Endpoints
時間枠:Up to approximately two years
|
|
Up to approximately two years
|
|
PK characteristics of HMPL-760 in patients with R/R DLBCL when administered in combination with R-GemOx
時間枠:At the end of Cycle 4 (each cycle is 21 days)]
|
including but not limited to steady-state plasma concentrations of HMPL-760 pre-dose [trough concentrations (Ctrough)] and post-dose (C1h and C2h); If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. If possible, a population pharmacokinetic (PPK) model can be used to generate PK parameters. If necessary, it can also be combined with other studies for model analysis. |
At the end of Cycle 4 (each cycle is 21 days)]
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Biomarker assessment
時間枠:Up to approximately two years
|
Detect tumor driver gene mutations in tissue and blood samples, such as MYD88 and CD79B, etc, and explore the relationship between their mutation status and drug efficacy. |
Up to approximately two years
|
|
To explore the metabolite profile of HMPL-760 in combination with R-GemOx in tumor patients
時間枠:Up to approximately two years
|
Human metabolites of HMPL-760 when co-administered with R-GemOx |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
時間枠:Up to approximately two years
|
maximum concentration in steady-state (Cmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
時間枠:Up to approximately two years
|
time to maximum concentration in steady-state (Tmax,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
時間枠:Up to approximately two years
|
Area Under the Curve at steady state refers to the area under the plasma concentration-time curve during a dosing interval at steady state conditions (AUC,ss) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
時間枠:Up to approximately two years
|
The rate at which the drug is eliminated from the body (CL/F) (if applicable ) |
Up to approximately two years
|
|
Pharmacokinetic parameters of gemcitabine and oxaliplatin when combined with HMPL-760
時間枠:Up to approximately two years
|
The distribution volume calculated based on the terminal elimination phase (Vz/F )(if applicable) |
Up to approximately two years
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Weili Zhao、Ruijin Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2025-760-00CH1
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。